Last reviewed · How we verify
TNF alpha inhibitors
TNF alpha inhibitors block tumor necrosis factor-alpha, a key inflammatory cytokine that drives immune-mediated inflammation.
TNF alpha inhibitors block tumor necrosis factor-alpha, a key inflammatory cytokine that drives immune-mediated inflammation. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | TNF alpha inhibitors |
|---|---|
| Sponsor | Prof. Roberto Giacomelli |
| Drug class | TNF alpha inhibitor |
| Target | TNF-α (tumor necrosis factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TNF-α is a central pro-inflammatory cytokine produced by macrophages, T cells, and other immune cells. By neutralizing or blocking TNF-α signaling through monoclonal antibodies, receptor antagonists, or TNF-α converting enzyme inhibitors, these drugs suppress excessive inflammatory responses. This mechanism is particularly effective in autoimmune and inflammatory conditions where TNF-α overproduction drives pathology.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
- Juvenile idiopathic arthritis
Common side effects
- Increased infection risk (including tuberculosis, fungal infections)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Malignancy risk (lymphoma, solid tumors)
- Demyelinating disease
- Heart failure exacerbation
Key clinical trials
- Lumbar Spinal Fibrosis and TNF Alpha Inhibition (PHASE3)
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Dental Implant Healing With TNF-Alpha Inhibitors (NA)
- A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (PHASE2)
- Neutropenia With TNF-α Inhibitors
- Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC (PHASE1)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNF alpha inhibitors CI brief — competitive landscape report
- TNF alpha inhibitors updates RSS · CI watch RSS
- Prof. Roberto Giacomelli portfolio CI